Use of heat‐treated clotting‐factor concentrates in patients with haemophilia and a high exposure to HTLV‐III
- 1 July 1985
- journal article
- research article
- Published by AMPCo in The Medical Journal of Australia
- Vol. 143 (1) , 11-13
- https://doi.org/10.5694/j.1326-5377.1985.tb122758.x
Abstract
In a group of 126 Australian patients with haemophilia, who were receiving lyophilized clotting‐factor concentrates prepared from locally collected plasma, a high prevalence of antibody to human T‐ce...This publication has 17 references indexed in Scilit:
- INACTIVATION OF LYMPHADENOPATHY-ASSOCIATED VIRUS BY HEAT, GAMMA RAYS, AND ULTRAVIOLET LIGHTThe Lancet, 1985
- HTLV-III SEROPOSITIVITY IN EUROPEAN HAEMOPHILIACS EXPOSED TO FACTOR VIII CONCENTRATE IMPORTED FROM THE USAThe Lancet, 1984
- Aetiology of AIDS—antibodies to human T-cell leukaemia virus (type III) in haemophiliacsNature, 1984
- RECOVERY AND INACTIVATION OF INFECTIOUS RETROVIRUSES ADDED TO FACTOR VIII CONCENTRATESThe Lancet, 1984
- A Process for Preparation of ‘High‐Purity’ Factor VIII by Controlled Pore Glass TreatmentVox Sanguinis, 1984
- Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDSScience, 1984
- Simplified immunoradiometric assay for factor VIII coagulant antigenBritish Journal of Haematology, 1982
- A Factor VIII Concentrate of Intermediate Purity and Higher PotencyTransfusion, 1979
- The Specific Assay of Prower-Stuart Factor and Factor VIIActa Haematologica, 1961
- The Control of Dicumarol Therapy and the Quantitative Determination of Prothrombin and ProconvertinScandinavian Journal of Clinical and Laboratory Investigation, 1951